Clinical Trials List
Protocol NumberCA073-1022
Active
2024-07-01 - 2029-09-19
Phase II
Recruiting3
-
Trial Applicant
BRISTOL-MYERS SQUIBB (TAIWAN) LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Tsung-Jang Yeh Division of Hematology & Oncology
- Shih-Feng Cho Division of Hematology & Oncology
- 高育青 Division of Hematology & Oncology
- 王閔宏 Division of Hematology & Oncology
- Hui-Hua Hsiao Division of Hematology & Oncology
- Jeng-Shiun Du Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李思慧 Division of General Internal Medicine
- HSIN-AN HOU Division of General Internal Medicine
- MING YAO Division of General Internal Medicine
- Chien-Chin Lin Division of General Internal Medicine
- CHENG-HONG TSAI Division of General Internal Medicine
- MEI-FANG CHENG Division of General Internal Medicine
- Huai-Hsuan Huang Division of General Internal Medicine
- 田豐銘 Division of General Internal Medicine
- SHAN-CHI YU Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- Wen-Chien Chou Division of General Internal Medicine
- 劉高郎 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 馬銘君 Division of Hematology & Oncology
- 林偉哲 Division of Hematology & Oncology
- 劉鴻霖 Division of Hematology & Oncology
- 黃永成 Division of Hematology & Oncology
- 邱玲榕 Division of Hematology & Oncology
- Hong jie Chen Division of Hematology & Oncology
- 廖碧涵 Division of Hematology & Oncology
- 許獻文 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
6 participants
-
Global
90 participants
